Inactivated H1N1 influenza vaccine (NIAID)

The inactivated H1N1 influenza vaccine (NIAID) refers to a group of monovalent inactivated vaccines evaluated by the National Institute of Allergy and Infectious Diseases (NIAID) during the 2009 H1N1 influenza pandemic. These vaccines were produced by manufacturers such as Sanofi Pasteur and CSL and were designed to protect against the A/California/07/2009 (H1N1)pdm09-like virus strain. NIAID conducted multiple Phase II clinical trials to assess the safety and immunogenicity of these vaccines at different dose levels (typically 15 mcg and 30 mcg) and to determine the impact of adjuvants, such as GSK's AS03, on the immune response. The trials included diverse populations such as healthy adults, the elderly, and pregnant women. The vaccine works by presenting inactivated viral particles to the immune system, primarily targeting the hemagglutinin (HA) protein to induce neutralizing antibodies.

Other names

2009 H1N1 influenza vaccineH1N1 monovalent vaccineH-1N1 monovalent vaccineH 1N1 monovalent vaccineSanofi Pasteur H1N1 vaccineCSL H1N1 vaccine2009 H1N1 monovalent inactivated influenza vaccine